Introduction
In children and adolescents, allogeneic haematopoietic stem cell transplantation (allo-HSCT) not only plays an important role in the treatment of malignant diseases and acquired BM failures, but it is also applied as an effective therapy for a wide range of inborn disorders, including congenital immunodeficiences, some inherited metabolic diseases, hereditary BM failures and haemoglobinopathies.
The paediatric population in 19 central and eastern European countries amounts to approximately 80 million children and adolescents p18 years of age. According to western European standards (mean of 19.0 HSCTs/ 1 million/year), this population requires a yearly total of around 1500-1600 haematopoietic stem cell transplantation (HSCT). 2 Due to the financial conditions, which were the result of the political situation, the contemporary history of paediatric HSCT in eastern European countries, as compared to Western countries, began more than 10 years later, that is, in the mid-1980s. However, at the end of the 1980s, political and then financial situations started to change. Furthermore, in 2004 and 2007, some eastern European countries became members of the EU. Therefore, it is important to evaluate development, recent achievements and needs of eastern European countries in the field of paediatric HSCT.
The purpose of the study was as follows: (1) to analyse the development of paediatric HSCT activity, that is, in recipients p18 years of age, in eastern European countries up to the end of 2004; (2) to compare paediatric HSCT activity in eastern European countries before and after 31 December 1998; (3) to characterize the recent status of paediatric HSCT activity in eastern European countries and (4) to compare day þ 100 TRM in recipients p18 years of age in eastern European countries before and after 1 January 1999 according to the type of transplantation and centre category.
Study design and methods

Study design
The following 19 countries are considered eastern European countries: Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Moldavia, Poland, Romania, Russia, Serbia and Montenegro, Slovakia, Slovenia and Ukraine.
Only patients p18 years of age at the time of autologous or allogeneic HSCT for malignant or non-malignant disease were eligible for this study. Data collection and analysis were based on the EBMT Registry data concerning eligible recipients transplanted till 31 December 2004 by transplant teams from eastern European countries and reported to the EBMT Registry using MED-A forms. Centres were classified as category '1' when they registered only children, category '2' when more than 25% of registered patients were children or category '3' when less than 25% of registered patients were children.
The following variables have been analysed on a yearly basis: (1) number and category of centres performing HSCT in children, (2) total number of HSCTs, (3) type of transplant (autologous or allogeneic), (4) type of donor for allogeneic HSCT (matched sibling donors (MSD), unrelated donors (UD) and mismatched family donors (MMFD)), (5) haematopoietic stem cell (HSC) source (BM, peripheral blood (PB) and cord blood (CB)), (6) indications for HSCT and (7) day þ 100 TRM.
Activity survey and statistical analysis
The data on transplants were summarized in absolute numbers and calculated as paediatric transplant rates of HSCTs per 10 million of the paediatric population in a given country based on population data obtained from the United States Census Office (www.census.gov). Transplant rates were evaluated according to the total number of HSCTs, autologous HSCT (auto-HSCT) and allo-HSCT. For continuous variables, the median was taken as a cut point. Probability of 100-day TRM was estimated using the product-limit method. Data management and statistical analyses were performed with SPSS (SPSS Inc., Chicago, IL, USA) software packages by Myriam Labopin, EBMT Statistician for the Acute Leukaemia WP Registry.
Results
Participating teams, team densities, centre category and yearly number of allo-HSCT per centre Between 1985 and 2004, the number of centres performing and reporting HSCT on children increased from 1 in 1985 to 24 in 2003 ( Figure 1) . However, the total number of centres reporting paediatric HSCT throughout the whole study period was actually 37, although not all of these teams performed paediatric HSCT each year, especially in category 3 centres.
In 2003, among the 24 eastern European transplant centres reporting data to the EBMT, 3 (12.5%) performed exclusively auto-HSCT, whereas the remaining 21 (87.5%) carried out auto-and/or allo-HSCT. Fewer than 5 allo-HSCT were performed in 9 (42.8%) of them, while between 5 and 10 were carried out in 7 centres (33.3%), between 11 and 20 in 2 (9.5%) and more than 20 in 3 (14.3%). Thus, only 5 centres (23.8%) performed more than 10 alloHSCTs. Regarding the type of HSCT, 1053 (45%) children underwent auto-HSCT, whereas 1289 (55%) underwent allo-HSCT. The first allo-HSCT was performed in 1985, whereas the first auto-HSCT was performed 3 years later in 1988.
The total yearly number of reported paediatric HSCTs rose from 1 in 1985 to 358 in 2003 and included 197 alloHSCTs and 161 auto-HSCTs (Figure 2 ). In countries performing paediatric HSCTs, the median team density (teams/10 million children) was 8 (range 1-28) and the median rate (per 10 million children) of total paediatric, allogeneic and auto-HSCTs was 70 (range 5-410), 35 (range 3-120) and 35 (range 3-290), respectively (Table 2) . However, in 2003, no paediatric HSCTs were reported to the EBMT Registry from Albania, Belarus, Bosnia and Herzegovina, Macedonia, Moldavia and Ukraine, that is, from low-income countries as defined by the World Bank (www.worldbank.org). The first allo-HSCT performed on a child with a malignant disease (AML) was reported in 1985 ( Figure 4) . The yearly number of allo-HSCTs for malignant diseases systematically increased until 1989, followed by a marked acceleration of this increase until 1998. Among malignant diseases, ALL was not only the major indication for allo-HSCT, but in addition, the number of children transplanted for ALL was continuously growing. Such an increase, however less pronounced, was also observed in children with AML and MDS. The number of allo-HSCT for CML was stable after 1999, while in children with lymphoma and solid tumours this number was stable and very low. In eastern European countries, the first three allo-HSCTs for acquired and congenital non-malignant diseases were performed in children with SAA in 1987 ( Figure 5 ). After that time, but especially after 1998, there was a continuous increase in the yearly number of allo-HSCTs in children with non-malignant diseases, particularly in children with SAA (from 3 to 24 in 2003) and immunodeficiencies (from 1 in 1992 to 14 in 2003), although it was less evident in children with inborn errors of metabolism and with Fanconi anaemia.
Indications for auto-HSCT
Out of 1053 recipients of auto-HSCT, 168 (16%) were transplanted for neuroblastoma, 129 (12.2%). for NHL, 124 (11.7%) for AML, 114 (10.8%) for ALL, 109 (10.4%) for Hodgkin's disease, 62 (5.9%) for Ewing's sarcoma, Day þ 100 TRM before and after 31 December 1998 Concerning donor type and time period, the day þ 100 TRM after MSD-HSCT was 14 ± 3% p1998 and 7 ± 1% between 1999 and 2004, while in recipients of MUD-HSCT it was 34±7 and 15±2% and after MMFD-HSCT 45±12 and 21 ± 3%, respectively. After allo-HSCT, the early TRM in category 1 centres accounted for 16±3% before 1999 and 12 ± 1% between 1999 and 2004, in category 2 centres it was 19 ± 4 and 13 ± 3% and in category 3 centres 22±4 and 15±4%, respectively, while after auto-HSCT it was 7 ± 3 and 4 ± 1%, 12 ± 4 and 7 ± 3%, and 6 ± 2 and 4 ± 3% according to centre category and time period analysed, respectively.
Discussion and the EBMT/ESH Outreach Programme overview
This is the first report that evaluates and demonstrates the development and recent activity in the field of HSCT in the paediatric population, which is made up of approximately 80 million children in the eastern European countries.
The history of paediatric HSCT in the eastern European countries started in 1985 with an MSD-BMT performed on a child suffering from AML, and hence this report analyses data from 1985 to 2004. However, data concerning 2004 were incomplete; therefore, 2003 data were often considered more representative in this report.
Generally, between 1985 and 2004 in eastern European countries, significant progress was made in the domain of paediatric HSCT. Namely, there was an increase in the number of paediatric transplant centres, with a predominance of category '1' centres, and a growing number of all types of HSCTs performed on patients p18 years for all the malignant and non-malignant diseases that were considered suitable for treatment by HSCT. 1 Similar trends have been observed in eastern European countries with regard to an increasing number of UD-HSCT, predominance of PB as a source of HSC for autologous transplantation and for allo-HSCT from UD, increasing number of auto-HSCT for neuroblastoma and decreasing number of autologous transplants in children with acute leukaemias. [2] [3] [4] [5] In addition, after 1 January 1999, significant reduction of the day þ 100 TRM has been achieved in relation to all types of HSCTs (MSD, MMFD and MUD) and all three categories of transplant centres, which become comparable with early TRM observed in western European paediatric transplant centres. 6 It is of interest that as in analysis concerning Western countries, 6 it was found that TRM depends also on centre category; however, only onefifth of centres performed more than 10 paediatric allo-HSCT per year, and around one-fifth of paediatric HSCTs have been undertaken in category '3' transplant centres.
On the other hand, as compared to western European standards, only one-third of all the needs of the paediatric population from eastern European countries are fulfilled in the HSCT domain, and there are significant differences among these countries, including countries that to date have not registered any paediatric HSCTs. These differences are the result of the financial situation in the individual countries, and rely on the Gross National Income per capita (GNI/capita) as was proven by Gratwohl et al. 2 These latter countries are especially in need of support in the areas of education, building of infrastructures and implementation of standards.
These are among the reasons why, in 2001, the EBMT in collaboration with the European School of Haematology 
